Aucatzyl, a therapy to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia has received FDA approval. Aucatzyl joins Gilead’s Tecartus and Novartis’ Kymriah. Autolus has wrapped up all pre-launch activities and will now move to finish the final steps involved in onboarding treatment centers.
Click here to read the entire article.